Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of the Administration of Ornithine Phenylacetate in Patients With Cirrhosis and Upper Gastrointestinal Bleeding

Trial Profile

Effects of the Administration of Ornithine Phenylacetate in Patients With Cirrhosis and Upper Gastrointestinal Bleeding

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 05 Oct 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ornithine phenylacetate (Primary)
  • Indications Gastrointestinal haemorrhage; Liver cirrhosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Oct 2015 Results published in Ocera Therapeutics media release.
    • 23 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 18 Feb 2015 Top-line results published in an Ocera Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top